By Paige Minemyer
As the COVID-19 vaccine rollout continues, payers are gearing up to play a key role in easing vaccine fears and hesitancy.
read more
By Eric Sagonowsky
Johnson & Johnson execs have assured investors and officials that the company is "comfortable" hitting its vaccine delivery targets. But with its U.S. rollout underway, the pharma giant has run into some supply problems in Europe, Reuters reports.
read more
By Paige Minemyer
The healthcare giant released its annual Health Trends Report on Tuesday, and the analysis projects 10 industry trends that are likely to define 2021 in healthcare.
read more
By Fraiser Kansteiner
As Eli Lilly hustles to make 1 million doses of its COVID-19 antibody cocktail by midyear, the company's manufacturing chief is heading for the exit. Myles O’Neill will pass the mantle to Edgardo Hernandez, now SVP of global parenteral drug product and device manufacturing. Meanwhile, the company's top compliance exec will also retire, handing the baton to a Lilly insider.
read more
By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale
PhARMA has appealed to President Biden to oppose a push to suspend the TRIPS Agreement, which protects intellectual property. The FDA has approved the first at-home COVID-19 testing kit which does not require a prescription. And more.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Beth Snyder Bulik
The Russian-developed Sputnik V coronavirus vaccine nabbed verified status from Twitter last week, immediately doubling down on its broadcasting wave of tweets, retweets and plenty of American-style attitude. But is the now-authenticated social media account a pharma influencer case study or a cautionary tale of disinformation?
read more
By Robert King
Providence posted a $306 million operating loss in 2020 due to higher expenses and a drop in patient volume stemming from the pandemic.
read more
By Eric Sagonowsky
GlaxoSmithKline managed to notch some wins during the pandemic-challenged year of 2020, but COVID-19 took its toll—not only on the British pharma's finances, but on CEO Emma Walmsley’s pay, too.
read more
